Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC Children's Leukemia Cooperative Group (CLCG).

abstract：:Patients with poor-risk leukemia have a high relapse rate despite allogeneic transplant. We report on the phase-2 trial of an intensified allogeneic transplant regimen whose aim was tolerable toxicity and durable remission. Study patients (n=30) had unfavorable first remission cytogenetics, progression from myelodyspl...

journal_title：Bone marrow transplantation

authors： Stein AS,O'Donnell MR,Synold TW,Dagis AC,Tsirunyan A,Nademanee AP,Parker PM,Pullarkat VA,Snyder DS,Spielberger RT,Wong JY,Alvarnas JC,Thomas SH,Forman SJ

更新日期：2011-09-01 00:00:00

abstract：:The transfer of cytotoxic effector cells reduces the risk of relapse after allogeneic BMT. Two murine leukemia cell lines, A20 (B lymphocytic) and WEHI-3 (myelomonocytic), were used to investigate antileukemic effector mechanisms operating independently from graft-versus-host disease (GVHD). Different results were obt...

journal_title：Bone marrow transplantation

authors： Uharek L,Glass B,Gaska T,Zeiss M,Gassmann W,Löffler H,Müller-Ruchholtz W

更新日期：1993-01-01 00:00:00

abstract：:Eight children underwent reduced-intensity stem cell transplantation (RIST) from an HLA-matched sibling. They received a fludarabine-melphalan based preparative regimen. Stem cell source was bone marrow, and GVHD prophylaxis consisted of cyclosporine A alone. Acute GVHD grade II-IV and grade III-IV were observed in fo...

journal_title：Bone marrow transplantation

authors： Inoue M,Okamura T,Yasui M,Sawada A,Sakata N,Koyama M,Sakata A,Takeshita Y,Kouroki M,Yagi K,Kawa K

更新日期：2006-03-01 00:00:00

abstract：:Invasive fungal infections are associated with significant morbidity and mortality among immunocompromised patients. Recent advances in antifungal development have afforded us more pharmacologic compounds to choose from when managing these fungal infections. The role of combination antifungal therapy has been well est...

journal_title：Bone marrow transplantation

authors： Johnson MD,Perfect JR

更新日期：2007-08-01 00:00:00

abstract：:To analyze the incidence, characteristics and risk factors of hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning (allo-RIC), we conducted a retrospective study in three Spanish centers. We analyzed 452 consecutive patients receiving allo-RIC. Of these, 92 patient...

journal_title：Bone marrow transplantation

authors： Barba P,Martino R,Perez-Simón JA,Fernández-Avilés F,Piñana JL,Valcárcel D,Campos-Varela I,Lopez-Anglada L,Rovira M,Novelli S,Lopez-Corral L,Carreras E,Sierra J

更新日期：2012-10-01 00:00:00

abstract：:Data from autologous peripheral blood progenitor cell (PBPC) transplant recipients were used for cost analysis and modelling so as to link the main intervention procedures and clinical events to resource use and costs. This cohort consisted of 64 patients from 4 to 62 years old at transplantation (mean, 36.9 years) wh...

journal_title：Bone marrow transplantation

authors： Barosi G,Marchetti M,Alessandrino P,Locatelli F,Casula S,Lunghi M,Cazzola M,Giraldi E,Bernasconi C

更新日期：1999-04-01 00:00:00

abstract：:We present three patients with aggressive non-Hodgkin's B-cell lymphoma (NHL) who received anti-CD19 chimeric antigen receptor T (CAR T) cells therapy after failure of several lines of chemotherapy that developed pseudo-progression. One-week clinical and radiological findings were consistent with tumor progression. Po...

journal_title：Bone marrow transplantation

authors： Danylesko I,Shouval R,Shem-Tov N,Yerushalmi R,Jacoby E,Besser MJ,Shimoni A,Davidson T,Beider K,Mevorach D,Fried S,Nagler A,Avigdor A

更新日期：2020-12-03 00:00:00

abstract：:We retrospectively studied a series of 23 patients (median age 50 years, range 29-59 years) with multiple myeloma (MM), treated in first relapse by a sequential autologous-allogeneic tandem approach. Tandem transplantation (TT) consisted in high dose melphalan (HDT) and auto-SCT followed by an (allo-SCT) preceded by t...

journal_title：Bone marrow transplantation

authors： Karlin L,Arnulf B,Chevret S,Ades L,Robin M,De Latour RP,Malphettes M,Kabbara N,Asli B,Rocha V,Fermand JP,Socie G

更新日期：2011-02-01 00:00:00

abstract：:G-CSF accelerates neutrophil recovery after autologous peripheral blood progenitor cell transplantation (aPBPCT), although the optimal timing for its administration is currently unknown. In order to establish the role and the optimal timing of administration of G-CSF after immunoselected CD34+ aPBPCT, we analyzed the ...

journal_title：Bone marrow transplantation

authors： Piccirillo N,Sica S,Laurenti L,Chiusolo P,La Barbera EO,Sorà F,Leone G

更新日期：1999-06-01 00:00:00

abstract：:Pure red cell aplasia (PRCA) is characterized by a selective marrow aplasia of the erythroid compartment. Immunosuppressive therapy achieves good results in about 25% of cases, but relapses are frequent. Autologous or allogeneic haematopoietic stem cell transplantation (HSCT) may be valuable in selected patients. Here...

journal_title：Bone marrow transplantation

authors： Musso M,Porretto F,Crescimanno A,Polizzi V,Scalone R

更新日期：2004-04-01 00:00:00

abstract：:The aim of this study was to define factors that significantly influence the early kinetics of donor chimerism after transplantation. In a retrospective study, the percentage of donor chimerism in peripheral blood measured with sex-chromosome-specific probes and fluorescence-in situ hybridization was analyzed in 184 r...

journal_title：Bone marrow transplantation

authors： Mohr B,Koch R,Thiede C,Kroschinsky F,Ehninger G,Bornhäuser M

更新日期：2004-12-01 00:00:00

abstract：:We retrospectively analyzed the outcome of 67 patients with breast (n=24), ovarian (n=11) or testicular cancer (n=32) treated for relapse after high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) transplantation. Treatment, survival and toxicity were analyzed. Patients with breast, ovarian or testicular...

journal_title：Bone marrow transplantation

authors： Bojko P,Akca A,Seeber S

更新日期：2003-06-01 00:00:00

abstract：:Allogeneic hematopoietic cell transplantation (allo-HCT) for patients with AML is increasingly able to impact the historically poor outcomes in this disease. Nonetheless, even with transplant, the rates of post-HCT relapse are unacceptably high, and remain a great challenge in the treatment of patients with AML. Maint...

journal_title：Bone marrow transplantation

authors： Brunner AM,Fathi AT,Chen YB

更新日期：2016-11-01 00:00:00

abstract：:Chimerism studies after allogeneic BMT are performed to determine the donor and/or recipient origin of peripheral blood and marrow lymphoid and hematopoietic cells. These studies have been performed mostly in leukemias and aplastic anemia. We report DNA-based chimerism studies in three patients transplanted for advanc...

journal_title：Bone marrow transplantation

authors： Martino R,Brunet S,García A,Sureda A,Soler J,Martínez C,Domingo-Albós A,Baiget M

更新日期：1995-12-01 00:00:00

abstract：:Bone marrow transplant-associated thrombotic microangiopathy (BMT-TM) ranges in severity from a self-limiting to a fatal disorder. There is no specific therapy for this condition to date. We have previously described a simple clinical grading system (grade 0-4) for BMT-TM; patients with grade 3-4 BMT-TM do poorly. A p...

journal_title：Bone marrow transplantation

authors： Zeigler ZR,Shadduck RK,Nath R,Andrews DF 3rd

更新日期：1996-01-01 00:00:00

abstract：:Rapid identification of a matched unrelated donor is essential for patients in need of hematopoietic SCT. We carried out a retrospective evaluation of 549 unrelated donor searches (UDSs), which were completed in 2005 for 23 German transplant centers. On the basis of the patient's HLA-DRB1 allele and DRB1-DQB1 haplotyp...

journal_title：Bone marrow transplantation

authors： Hirv K,Bloch K,Fischer M,Einsiedler B,Schrezenmeier H,Mytilineos J

更新日期：2009-10-01 00:00:00

abstract：:A phase I/II trial evaluated early administration and dose escalation of interleukin (IL)-2 with granulocyte macrophage colony stimulating factor (GM-CSF) post-transplant. Following melphalan (200 mg/m(2)) and an autologous transplant, IL-2 was initiated (day 0) and continued for 4 weeks. GM-CSF (250 mcg/m(2)/day) beg...

journal_title：Bone marrow transplantation

authors： Meehan KR,Wu J,Bengtson E,Hill J,Ely P,Szczepiorkowski Z,Kendall M,Ernstoff MS

更新日期：2007-06-01 00:00:00

abstract：:Successful stem cell mobilization and collection is possible in B-CLL after a favorable response to preceding chemotherapy, and also after treatment with the new nucleoside analogues fludarabine and cladribine. A poor response, on the other hand, seemed to predict a mobilization failure. CD34+ cell selection resulted ...

journal_title：Bone marrow transplantation

authors： Itälä M,Pelliniemi TT,Rajamäki A,Remes K

更新日期：1997-04-01 00:00:00

abstract：:Thirty-five patients with myelodysplastic syndromes (MDS) were treated with BMT between 1986 and 1994. Their median age was 41 years (range 23-60). Thirteen patients had transfusion-dependent refractory anaemia (RA). Twenty-two patients suffered from more advanced stages of MDS, 15 being in complete remission (CR) aft...

journal_title：Bone marrow transplantation

authors： Mattijssen V,Schattenberg A,Schaap N,Preijers F,De Witte T

更新日期：1997-04-01 00:00:00

abstract：:Increased use of novel agents and autologous stem cell transplantation has led to a significant improvement in PFS and overall survival in patients with multiple myeloma. Despite improved treatment strategies, most patients eventually relapse due to persistent low levels of disease in the bone marrow. Increasingly sen...

journal_title：Bone marrow transplantation

authors： Sherrod AM,Hari P,Mosse CA,Walker RC,Cornell RF

更新日期：2016-01-01 00:00:00

abstract：:We investigated the serial changes in the blood CsA concentration during the switch from continuous intravenous infusion to twice-daily oral administration in allogeneic hematopoietic stem cell transplant recipients (n=12). The microemulsion form of CsA, Neoral, was started at twice the last dose in intravenous infusi...

journal_title：Bone marrow transplantation

authors： Kimura S,Oshima K,Okuda S,Sato K,Sato M,Terasako K,Nakasone H,Kako S,Yamazaki R,Tanaka Y,Tanihara A,Higuchi T,Nishida J,Kanda Y

更新日期：2010-06-01 00:00:00

abstract：:We report a case of unexplained graft failure in a 33-year-old man who received an allogeneic bone marrow graft that contained a donor-recipient mismatch involving the highly immunogenic NA1 neutrophil-specific alloantigen system. Laboratory and clinical data suggest that an alloimmune process related to the neutrophi...

journal_title：Bone marrow transplantation

authors： Klumpp TR,Herman JH,Mangan KF,Macdonald JS

更新日期：1993-03-01 00:00:00

abstract：:Intravenous cyclosporin was administered continuously to 18 consecutive marrow transplant recipients. Blood samples taken from the single lumen central venous line through which the cyclosporin was administered showed invariably high concentrations. Toxic levels were still present after discontinuation of cyclosporin ...

journal_title：Bone marrow transplantation

authors： de Witte T,Hoitsma A,Manoiu MM,Janssen J

更新日期：1986-12-01 00:00:00

abstract：:Binding and human complement-mediated T and B lymphocyte lysis were investigated in bone marrow samples obtained from 15 normal donors and 12 patients with a variety of malignant disorders undergoing marrow cryopreservation prior to autologous bone marrow transplantation. All marrow samples were obtained during remiss...

journal_title：Bone marrow transplantation

authors： Gazitt Y,Or R,Mumcuoglu M,Slavin S

更新日期：1987-12-01 00:00:00

abstract：:We conducted an open label, randomised clinical trial to compare amphotericin B colloidal dispersion (ABCD, Amphocil) 2 mg/kg/day intravenously with fluconazole 200 mg/day orally, for the prevention of fungal disease in neutropenic patients with haematological malignancies. In the event of unresolved fever after 4 day...

journal_title：Bone marrow transplantation

authors： Timmers GJ,Zweegman S,Simoons-Smit AM,van Loenen AC,Touw D,Huijgens PC

更新日期：2000-04-01 00:00:00

abstract：:For patients with ALL who relapse following allo-SCT, only a second SCT provides a realistic chance for long-term disease remission. We retrospectively analyzed the outcomes of 31 patients with relapsed ALL after a prior allo-SCT, who received a second SCT (SCT2) at our center. With a median follow-up of 3 years, 1- a...

journal_title：Bone marrow transplantation

authors： Poon LM,Bassett R Jr,Rondon G,Hamdi A,Qazilbash M,Hosing C,Jones RB,Shpall EJ,Popat UR,Nieto Y,Worth LL,Cooper L,De Lima M,Champlin RE,Kebriaei P

更新日期：2013-05-01 00:00:00

abstract：:Allogeneic hematopoietic SCT (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS). However, many patients cannot find an HLA-matched donor. We have developed a new protocol for HLA-mismatched (including haploidentical) HSCT using G-CSF-primed BM plus G-CSF-mobilized PBSCs without in vitro...

journal_title：Bone marrow transplantation

authors： Chen Y,Liu K,Xu L,Chen H,Liu D,Zhang X,Shi H,Han W,Wang Y,Zhao T,Wang J,Wang J,Huang X

更新日期：2010-08-01 00:00:00

abstract：:Allogeneic hematopoietic stem cell transplantation (HSCT) can be used to treat children with refractory acute myeloid leukemia (AML). This retrospective analysis aimed to describe the outcomes and risk factors in such children. Data were collected through the nation-wide registry program in Japan. A total of 417 AML (...

journal_title：Bone marrow transplantation

authors： Okamoto Y,Kudo K,Tabuchi K,Tomizawa D,Taga T,Goto H,Yabe H,Nakazawa Y,Koh K,Ikegame K,Yoshida N,Uchida N,Watanabe K,Koga Y,Inoue M,Kato K,Atsuta Y,Ishida H

更新日期：2019-09-01 00:00:00

abstract：:Immune recovery was retrospectively analyzed in a cohort of 41 patients with acute leukemia, myelodysplastic syndrome and nonmalignant diseases, who received αβ T- and B-cell-depleted allografts from haploidentical family donors. Conditioning regimens consisted of fludarabine or clofarabine, thiotepa, melphalan and se...

journal_title：Bone marrow transplantation

authors： Lang P,Feuchtinger T,Teltschik HM,Schwinger W,Schlegel P,Pfeiffer M,Schumm M,Lang AM,Lang B,Schwarze CP,Ebinger M,Urban C,Handgretinger R

更新日期：2015-06-01 00:00:00

abstract：:The term 'an HLA matched donor' is in general used without giving exact information on the level of resolution of the HLA typing. This can lead to misunderstandings. A proposal is formulated to agree on using six match categories according to the HLA typing technique used to indicate the level of confidence of the mat...

journal_title：Bone marrow transplantation

authors： van Rood JJ,Oudshoorn M

更新日期：1998-07-01 00:00:00